Acadia’s Elizabeth H.Z. Thompson to retire October 23

Acadia is identifying a replacement while Dr. Thompson intends to provide limited consulting services through December 31, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Acadia Pharmaceuticals Inc. said Elizabeth H.Z. Thompson, Ph.D., will stop serving as an employee and as Executive Vice President, Head of Research and Development, effective October 23, 2026. She informed the company on April 27, 2026, of her planned retirement for personal reasons. Effective October 23, she will be retained as a consultant and intends to provide limited consulting services through December 31, 2026. Acadia is identifying a replacement; the company noted that Dr. Thompson may decide not to serve as a consultant.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Retirement notice date: April 27, 2026 Role transition date: October 23, 2026 Intended consulting through: December 31, 2026

3 metrics

Retirement notice date April 27, 2026 Date Dr. Thompson informed Acadia of her planned retirement

Role transition date October 23, 2026 Effective date she stops serving as an employee and as Head of Research and Development

Intended consulting through December 31, 2026 End date for her intended limited consulting services

Key Terms

forward-looking statements, Private Securities Litigation Reform Act of 1995, Securities Exchange Act of 1934

3 terms

forward-looking statements regulatory

"contains forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Private Securities Litigation Reform Act of 1995 regulatory

"within the meaning of the Private Securities Litigation Reform Act of 1995"

Securities Exchange Act of 1934 regulatory

"requirements of the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Elizabeth H.Z. Thompson leave ACAD's R&D role?

She will no longer be an employee or serve as Head of Research and Development effective October 23, 2026.

Will Elizabeth H.Z. Thompson continue working with ACAD after leaving?

Effective October 23, 2026, Acadia will retain her as a consultant, and she intends to provide limited consulting services through December 31, 2026. The company noted that she may decide not to serve as a consultant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/23/2026 - 04:55 PM EDT Accepted by SEC EDGAR 10/23/2026 - 04:51 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): October 23, 2026

    

Acadia Pharmaceuticals Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	000-50768	06-1376651
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12830 El Camino Real, Suite 400
San Diego, California		92130
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (858) 558-2871

    

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ACAD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 1, 2026, on April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of Research and Development of Acadia Pharmaceuticals Inc. (the “Company”), informed the Company of her planned retirement from the Company for personal reasons. As of October 23, 2026, Dr. Thompson will no longer serve as an employee of the Company or function in her former role as Head of Research and Development. Also, effective October 23, 2026, Dr Thompson will be retained as a consultant by the Company and intends to provide limited consulting services to the Company through December 31, 2026. The Company is in the process of identifying Dr. Thompson’s replacement.

Forward-Looking Statements

This Current Report on Form 8-K (this “Current Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “will,” “intends” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this Current Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this Current Report include, but are not limited to, statements regarding Dr. Thompson’s continued service to the Company as a consultant, the duration of those consulting services, and the Company’s search for a replacement Head of Research and Development. Many factors may cause differences between current expectations and actual results, including the potential for Dr. Thompson to determine not to serve as a consultant to the Company. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this Current Report are discussed in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Acadia Pharmaceuticals Inc.

Date:	October 23, 2026	By:	/s/ Jennifer J. Rhodes
			Jennifer J. Rhodes Executive Vice President, Chief Legal Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document